


Partners



This leaflet is part of the project '738145 / TRANSPPOSE' which has received funding from the European Union's Health Programme (2014-2020). The content of this leaflet represents the views of the author only and is his/her sole responsibility; it cannot be considered to reflect the views of the European Commission and/or the Consumers, Health, Agriculture and Food Executive Agency or any other body of the European Union. The European Commission and the Agency do not accept any responsibility for use that may be made of the information it contains.



Co-funded by
the Health Programme
of the European Union



TRANSPOSE

www.transposeproject.eu

Grant Agreement 738145

TRANSfusion and transplantation
PrOtection and **SE**lection of donors

Over **5 million patients** in the EU annually receive transfusions or transplantations of substances of human origin (**SoHO**): **blood components, plasma-derived products, tissues & stem cells, germ cells for assisted reproductive technologies (ART) and organs.** These treatments significantly depend on the availability of SoHO obtained from more than **13 million European donors.**

What

TRANSPOSE is an EU co-funded project that aims at achieving the harmonization of the European donor selection and protection policies related to the SoHO donations, whilst keeping adequate health and safety protection of the recipient.

Who

The project Consortium consists of 24 partners in representation of 15 countries, including national Competent Authorities, European key organizations and Associations, stakeholders and academics.

When

The TRANSPOSE project will last 30 months (September 2017 – March 2020).; all the activities will be carried out in accordance with the timeline defined in the Grant Agreement (GA).

Why

In the “jungle” of the numerous existing European guidelines and protocols on donor selection and protection, the project was thought on the basis of the possibility to define a common framework, which should be regardless of the nationality or the kind of donation, starting from the current practices and scientific insights to protect both donors and recipients.

Specific objectives

1. **In-depth inventory** of current practices in donor selection and protection.
2. Gather relevant, available **knowledge in SoHO** organizations on tools to assess donor selection and protection criteria.
3. Knowledge about **benefits and pitfalls** of specific practices and expert opinions.
4. Perform a thorough **evaluation** of donation-related risks for donors and recipients.
5. Identify appropriate donor eligibility criteria for the protection of donors and recipients.
6. Develop **risk-based Guidelines** for the selection and protection of donors.
7. Develop **guiding principles** for the critical evaluation of existing donor eligibility criteria, and for the development and validation of **new/additional eligibility criteria**.
8. Identify minimum requirements and essential elements for a basic standardized donor and donor family questionnaire to gather relevant information through a valid, cost efficient and easily understood series of questions taking into account socio-economic, cultural and emotional factors, as well as **SoHO types**.
9. Develop a **basic standardized donor** and **donor family questionnaire** for different SoHO donation types.
10. Maximal validation of the donor health questionnaires and modules.
11. Develop a **training programme** for the proper use of the Guidelines and guiding principles by responsible organizations and responsible staff, including but not limited to relevant Competent Authority officials; SoHO establishments' medical advisors, senior donor physicians, executive nurses.



TRANSPOSE may facilitate the process of revising related EU Directives. Moreover, the developed guiding principles and Donor Selection & Protection Guidelines will assist EU Member States to implement policies in a consistent and clear-cut way.

Finally, a standard Donor Health Questionnaire with carefully guided local/regional/national customization will become available. It can be used widely and it will enable comparisons/benchmarking between Member States on the prevalence of certain risks and risky behaviors throughout Europe.

